{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:12:21Z","timestamp":1780495941941,"version":"3.54.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s11882-024-01135-z","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T19:18:26Z","timestamp":1710271106000},"page":"143-154","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Multidisciplinary Decision-Making\u2014ITAlian Consensus After Two Years of Real Practice on the Management of Severe Uncontrolled CRSwNP by Biologics (ITACA Study)"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5761-7018","authenticated-orcid":false,"given":"Eugenio","family":"De Corso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6628-2117","authenticated-orcid":false,"given":"Carlotta","family":"Pipolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Caminati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7389-2033","authenticated-orcid":false,"given":"Elena","family":"Cantone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Seccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0658-2449","authenticated-orcid":false,"given":"Lorenzo","family":"Cecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1383-105X","authenticated-orcid":false,"given":"Eustachio","family":"Nettis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9949-1177","authenticated-orcid":false,"given":"Massimiliano","family":"Garzaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2433-4761","authenticated-orcid":false,"given":"Giancarlo","family":"Ottaviano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Gelardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0378-8935","authenticated-orcid":false,"given":"Carlo","family":"Cavaliere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Heffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2244-373X","authenticated-orcid":false,"given":"Fabio","family":"Pagella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Trimarchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignazio","family":"La Mantia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8461-6042","authenticated-orcid":false,"given":"Sara","family":"Torretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7023-6746","authenticated-orcid":false,"given":"Davide","family":"Mattavelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Matucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vultaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5341-3309","authenticated-orcid":false,"given":"Gianluca","family":"Bellocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3479-297X","authenticated-orcid":false,"given":"Matteo","family":"Alicandri Ciufelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Passali","family":"FM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianenrico","family":"Senna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"1135_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2147\/JAA.S86251","volume":"9","author":"C Langdon","year":"2016","unstructured":"Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy. 2016;9:45\u201353. https:\/\/doi.org\/10.2147\/JAA.S86251.","journal-title":"J Asthma Allergy"},{"issue":"4","key":"1135_CR2","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2500\/ajra.2011.25.3613","volume":"25","author":"DC Lin","year":"2011","unstructured":"Lin DC, Chandra RK, Tan BK, et al. Association between severity of asthma and degree of chronic rhinosinusitis. Am J Rhinol Allergy. 2011;25(4):205\u20138. https:\/\/doi.org\/10.2500\/ajra.2011.25.3613.","journal-title":"Am J Rhinol Allergy"},{"issue":"1","key":"1135_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12931-018-0823-y","volume":"19","author":"CM Philpott","year":"2018","unstructured":"Philpott CM, Erskine S, Hopkins C, et al. Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study. Respir Res. 2018;19(1):129. https:\/\/doi.org\/10.1186\/s12931-018-0823-y.","journal-title":"Respir Res"},{"issue":"4","key":"1135_CR4","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.jaip.2017.09.020","volume":"6","author":"D Wu","year":"2018","unstructured":"Wu D, Bleier BS, Li L, et al. Clinical phenotypes of nasal polyps and comorbid asthma based on cluster analysis of disease history. J Allergy Clin Immunol Pract. 2018;6(4):1297-305.e1. https:\/\/doi.org\/10.1016\/j.jaip.2017.09.020.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1135_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.600","volume":"58","author":"WJ Fokkens","year":"2020","unstructured":"\u2022\u2022 Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58:1\u2013464. https:\/\/doi.org\/10.4193\/Rhin20.600. First international guideline which emphasizes the role of the endotype as an essential prerequisite for precision medicine, providing the essential foundation for the start of the use of biologics in normal clinical practice.","journal-title":"Rhinology"},{"issue":"1","key":"1135_CR6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-020-00218-1","volume":"6","author":"C Bachert","year":"2020","unstructured":"Bachert C, Marple B, Schlosser RJ, Hopkins C, Schleimer RP, Lambrecht BN, et al. Adult chronic rhinosinusitis. Nat Rev Dis Primers. 2020;6(1):86. https:\/\/doi.org\/10.1038\/s41572-020-00218-1.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"1135_CR7","doi-asserted-by":"publisher","first-page":"450","DOI":"10.2500\/aap.2021.42.210080","volume":"42","author":"DV Wallace","year":"2021","unstructured":"Wallace DV. Treatment options for chronic rhinosinusitis with nasal polyps. Allergy Asthma Proc. 2021;42(6):450\u201360. https:\/\/doi.org\/10.2500\/aap.2021.42.210080.","journal-title":"Allergy Asthma Proc"},{"key":"1135_CR8","doi-asserted-by":"publisher","unstructured":"\u2022 De Corso E, Bellocchi G, De Benedetto M, Lombardo N, Macchi A, Malvezzi L, et al. Biologics for severe uncontrolled chronic rhinosinusitis with nasal polyps: a change management approach. Consensus of the Joint Committee of Italian Society of Otorhinolaryngology on biologics in rhinology. Acta Otorhinolaryngol Ital. 2022;42(1):1\u201316. https:\/\/doi.org\/10.14639\/0392-100X-N1614. First Italian position paper published after the approval of biologics in Italy in which the value of multidisciplinarity is greatly stressed.","DOI":"10.14639\/0392-100X-N1614"},{"issue":"6","key":"1135_CR9","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3390\/jpm12060897","volume":"12","author":"E De Corso","year":"2022","unstructured":"De Corso E, Pipolo C, Cantone E, Ottaviano G, Gallo S, Canevari FRM, et al. Survey on Use of Local and Systemic Corticosteroids in the Management of Chronic Rhinosinusitis with Nasal Polyps: Identification of Unmet Clinical Needs. J Pers Med. 2022;12(6):897. https:\/\/doi.org\/10.3390\/jpm12060897.","journal-title":"J Pers Med"},{"issue":"1","key":"1135_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","volume":"147","author":"C Bachert","year":"2021","unstructured":"Bachert C, Han JK, Wagenmann M, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management. J Allergy Clin Immunol. 2021;147(1):29\u201336.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"1135_CR11","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.3390\/jpm13111531","volume":"13","author":"E De Corso","year":"2023","unstructured":"\u2022 De Corso E, Ottaviano G, Pipolo C, Cantone E, Mattavelli D, Alicandri-Ciufelli M, et al. Chronic Rhinosinusitis with Nasal Polyps: A Survey on Routine Management and Evaluation of Disease Control in Practice. J Pers Med. 2023;13(11):1531. https:\/\/doi.org\/10.3390\/jpm13111531. Italian survey from which the need for a clinical definition of disease control in clinical practice and for specific tools to measure it clearly emerges.","journal-title":"J Pers Med"},{"issue":"5","key":"1135_CR12","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","volume":"137","author":"P Tomassen","year":"2016","unstructured":"Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, Olze H, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137(5):1449-56.e4. https:\/\/doi.org\/10.1016\/j.jaci.2015.12.1324.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"1135_CR13","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.jaci.2018.03.004","volume":"141","author":"C Bachert","year":"2018","unstructured":"Bachert C, Zhang N, Hellings PW, Bousquet J. Endotype-driven care pathways in patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2018;141(5):1543\u201351. https:\/\/doi.org\/10.1016\/j.jaci.2018.03.004.","journal-title":"J Allergy Clin Immunol"},{"key":"1135_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13601-017-0157-8","volume":"7","author":"G De Greve","year":"2017","unstructured":"De Greve G, Hellings PW, Fokkens WJ, Pugin B, Steelant B, Seys SF. Endotype-driven treatment in chronic upper airway diseases. Clin Transl Allergy. 2017;7:22. https:\/\/doi.org\/10.1186\/s13601-017-0157-8.","journal-title":"Clin Transl Allergy"},{"key":"1135_CR15","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394:1638\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(19)31881-1.","journal-title":"Lancet"},{"key":"1135_CR16","doi-asserted-by":"publisher","unstructured":"van der Lans RJL, Fokkens WJ, Adriaensen GFJPM, Hoven DR, Drubbel JJ, Reitsma S. Real-life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps. Allergy 2022;77:670\u20134. https:\/\/doi.org\/10.1111\/all.15134.","DOI":"10.1111\/all.15134"},{"issue":"3","key":"1135_CR17","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","volume":"146","author":"P Gevaert","year":"2020","unstructured":"Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595\u2013605. https:\/\/doi.org\/10.1016\/j.jaci.2020.05.032.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1135_CR18","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jaci.2021.07.045","volume":"149","author":"P Gevaert","year":"2022","unstructured":"Gevaert P, Saenz R, Corren J, Han JK, Mullol J, Lee SE, et al. Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study. J Allergy Clin Immunol. 2022;149(3):957-65.e3. https:\/\/doi.org\/10.1016\/j.jaci.2021.07.045.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1135_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/alr.23219","volume":"14","author":"M Desrosiers","year":"2023","unstructured":"Desrosiers M, Diamant Z, Castelnuovo P, Hellings PW, Han JK, Peters AT, et al. Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24-week treatment-free follow-up. Int Forum Allergy Rhinol. 2023;14(1):18\u201331. https:\/\/doi.org\/10.1002\/alr.23219.","journal-title":"Int Forum Allergy Rhinol"},{"issue":"2","key":"1135_CR20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.4193\/Rhin22.200","volume":"61","author":"C Hopkins","year":"2023","unstructured":"Hopkins C, Han JK, Lund VJ, Bachert C, Fokkens WJ, Diamant Z, et al. Evaluating treatment response to mepolizumab in patients with severe CRSwNP. Rhinology. 2023;61(2):108\u201317. https:\/\/doi.org\/10.4193\/Rhin22.200.","journal-title":"Rhinology"},{"key":"1135_CR21","doi-asserted-by":"publisher","unstructured":"\u2022 De Corso E, Pipolo C, Cantone E, Ottaviano G, Gallo S, Trimarchi M, et al. Practical recommendations for managing severe chronic rhinosinusitis with nasal polyps in the era of biologics. Acta Otorhinolaryngol Ital. 2023;43(5):324\u201340. https:\/\/doi.org\/10.14639\/0392-100X-N2422 .\u00a0Italian position paper which highlights through a survey the needs that emerge from the daily use of biologics in normal clinical practice.","DOI":"10.14639\/0392-100X-N2422"},{"key":"1135_CR22","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1111\/all.13875","volume":"74","author":"WJ Fokkens","year":"2019","unstructured":"\u2022\u2022 Fokkens WJ, Lund V, Bachert C, Mullol J, Bjermer L, Bousquet J, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74:2312\u20139. https:\/\/doi.org\/10.1111\/all.13875. First paper in which the criteria for the indication of CRSwNPs to biological drugs are defined.","journal-title":"Allergy"},{"issue":"5","key":"1135_CR23","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3390\/jpm12050846","volume":"12","author":"E De Corso","year":"2022","unstructured":"De Corso E, Bil\u00f2 MB, Matucci A, Seccia V, Braido F, Gelardi M, et al. Personalized Management of Patients with Chronic Rhinosinusitis with Nasal Polyps in Clinical Practice: A Multidisciplinary Consensus Statement. J Pers Med. 2022;12(5):846. https:\/\/doi.org\/10.3390\/jpm12050846.","journal-title":"J Pers Med"},{"key":"1135_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2021.100592","volume":"14","author":"C Lombardi","year":"2021","unstructured":"Lombardi C, Asero R, Bagnasco D, Blasi F, Bonini M, Bussi M, et al. ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments. World Allergy Organ J. 2021;14: 100592. https:\/\/doi.org\/10.1016\/j.waojou.2021.100592.","journal-title":"World Allergy Organ J"},{"key":"1135_CR25","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/coa.13779","volume":"46","author":"C Hopkins","year":"2021","unstructured":"Hopkins C, McKenzie JL, Anari S, Carrie S, Ramakrishnan Y, Kara N, et al. British Rhinological Society consensus guidance on the use of biological therapies for chronic rhinosinusitis with nasal polyps. Clin Otolaryngol. 2021;46:1037\u201343. https:\/\/doi.org\/10.1111\/coa.13779.","journal-title":"Clin Otolaryngol"},{"key":"1135_CR26","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Fokkens WJ, De Corso E, Backer V, Bernal-Sprekelsen M, Bjermer L, von Buchwald C, et al. EPOS2020\/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP. Rhinology. 2024 Jan 13.\u00a0https:\/\/doi.org\/10.4193\/Rhin23.415. Epub ahead of print. PMID: 38217529. Expert opinion including new definitions such as Control of disease and Remission.","DOI":"10.4193\/Rhin23.415"},{"key":"1135_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40463-021-00493-2","volume":"50","author":"A Thamboo","year":"2021","unstructured":"Thamboo A, Kilty S, Witterick I, Chan Y, Chin CJ, Janjua A, et al. Canadian Rhinology Working Group consensus statement: biologic therapies for chronic rhinosinusitis. Otolaryngol Head Neck Surg. 2021;50:15. https:\/\/doi.org\/10.1186\/s40463-021-00493-2.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"25","key":"1135_CR28","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1200\/JCO.2012.42.0489","volume":"30","author":"DA Loblaw","year":"2012","unstructured":"Loblaw DA, Prestrud AA, Somerfield MR, Oliver TK, Brouwers MC, Nam RK, et al. American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology. J Clin Oncol. 2012;30(25):3136\u201340. https:\/\/doi.org\/10.1200\/JCO.2012.42.0489.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1135_CR29","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1097\/ACM.0000000000001812","volume":"92","author":"S Humphrey-Murto","year":"2017","unstructured":"Humphrey-Murto S, Varpio L, Wood TJ, Gonsalves C, Ufholz LA, Mascioli K, et al. The Use of the Delphi and Other Consensus Group Methods in Medical Education Research: A Review. Acad Med. 2017;92(10):1491\u20138. https:\/\/doi.org\/10.1097\/ACM.0000000000001812.","journal-title":"Acad Med"},{"issue":"3","key":"1135_CR30","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4193\/Rhin22.489","volume":"61","author":"WJ Fokkens","year":"2023","unstructured":"\u2022\u2022 Fokkens WJ, Viskens AS, Backer V, Conti D, De Corso E, Gevaert P, et al. EPOS\/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023. Rhinology. 2023;61(3):194\u2013202. https:\/\/doi.org\/10.4193\/Rhin22.489. Important update on indications for biologics and evaluation of success.","journal-title":"Rhinology"},{"issue":"7","key":"1135_CR31","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.mayocp.2023.02.013","volume":"98","author":"P Khoury","year":"2023","unstructured":"Khoury P, Akuthota P, Kwon N, Steinfeld J, Roufosse F. HES and EGPA: Two Sides of the Same Coin. Mayo Clin Proc. 2023;98(7):1054\u201370. https:\/\/doi.org\/10.1016\/j.mayocp.2023.02.013.","journal-title":"Mayo Clin Proc"},{"key":"1135_CR32","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.2174\/1570159X20666220420113513","volume":"12","author":"E Cantone","year":"2022","unstructured":"Cantone E, De Corso E, Ricciardiello F, Di Nola C, Grimaldi G, Allocca V, et al. Olfaction recovery following dupilumab is independent of nasal polyp reduction in CRSwNP. J Pers Med. 2022;12:1215. https:\/\/doi.org\/10.2174\/1570159X20666220420113513.","journal-title":"J Pers Med"},{"issue":"3","key":"1135_CR33","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1159\/000519228","volume":"183","author":"Q Wu","year":"2022","unstructured":"Wu Q, Zhang Y, Kong W, Wang X, Yuan L, Zheng R, et al. Which Is the Best Biologic for Nasal Polyps: Dupilumab, Omalizumab, or Mepolizumab? A Network Meta-Analysis. Int Arch Allergy Immunol. 2022;183(3):279\u201388. https:\/\/doi.org\/10.1159\/000519228.","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"1135_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12169","volume":"12","author":"Y Shen","year":"2022","unstructured":"Shen Y, Ke X, Hong S, Yang Y. Adverse events for biologics in patients with CRSwNP: A meta-analysis. Clin Transl Allergy. 2022;12(6): e12169. https:\/\/doi.org\/10.1002\/clt2.12169.","journal-title":"Clin Transl Allergy"},{"issue":"6","key":"1135_CR35","doi-asserted-by":"publisher","first-page":"538","DOI":"10.4193\/Rhin20.165","volume":"58","author":"S Reitsma","year":"2020","unstructured":"Reitsma S, Adriaensen G, Cornet ME, van Haastert RM, Raftopulos MH, Fokkens WJ. The Amsterdam Classification of Completeness of Endoscopic Sinus Surgery (ACCESS): a new CT-based scoring system grading the extent of surgery. Rhinology. 2020;58(6):538\u201343. https:\/\/doi.org\/10.4193\/Rhin20.165.","journal-title":"Rhinology"},{"issue":"3","key":"1135_CR36","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/alr.22505","volume":"10","author":"CA Loftus","year":"2020","unstructured":"Loftus CA, Soler ZM, Desiato VM, Koochakzadeh S, Yoo F, Storck KA, et al. Factors impacting revision surgery in patients with chronic rhinosinusitis with nasal polyposis. Int Forum Allergy Rhinol. 2020;10(3):289\u2013302. https:\/\/doi.org\/10.1002\/alr.22505.","journal-title":"Int Forum Allergy Rhinol"},{"issue":"11","key":"1135_CR37","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1002\/alr.23168","volume":"13","author":"AR Sedaghat","year":"2023","unstructured":"\u2022\u2022 Sedaghat AR, Caradonna DS, Chandra RK, Franzese C, Gray ST, Halderman AA, et al. Determinants of physician assessment of chronic rhinosinusitis disease control using EPOS 2020 criteria and the importance of incorporating patient perspectives of disease control. Int Forum Allergy Rhinol. 2023;13(11):2004\u201317. https:\/\/doi.org\/10.1002\/alr.23168. Important article where for the first time the importance of the patient's perception in the definition of disease control is underlined by Delphi method.","journal-title":"Int Forum Allergy Rhinol"},{"issue":"163","key":"1135_CR38","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0183-2021","volume":"31","author":"WW Busse","year":"2022","unstructured":"Busse WW, Mel\u00e9n E, Menzies-Gow AN. Holy Grail: the journey towards disease modification in asthma. Eur Respir Rev. 2022;31(163): 210183. https:\/\/doi.org\/10.1183\/16000617.0183-2021.","journal-title":"Eur Respir Rev"},{"issue":"1","key":"1135_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11882-023-01118-6","volume":"24","author":"M Caminati","year":"2024","unstructured":"\u2022\u2022 Caminati M, De Corso E, Ottaviano G, Pipolo C, Schiappoli M, Seccia V, et al. Remission in Type 2 Inflammatory Diseases: Current Evidence, Unmet Needs, and Suggestions for Defining Remission in Chronic Rhinosinusitis with Nasal Polyps. Curr Allergy Asthma Rep. 2024;24(1):11\u201323. https:\/\/doi.org\/10.1007\/s11882-023-01118-6. Systematic review on the need to define remission in nasal polyposis starting from the definitions of other type 2 diseases.","journal-title":"Curr Allergy Asthma Rep"},{"issue":"1","key":"1135_CR40","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40463-021-00519-9","volume":"50","author":"N Saydy","year":"2021","unstructured":"Saydy N, Moubayed SP, Bussi\u00e8res M, Janjua A, Kilty S, Lavigne F, et al. What is the optimal outcome after endoscopic sinus surgery in the treatment of chronic rhinosinusitis? A consultation of Canadian experts. J Otolaryngol Head Neck Surg. 2021;50(1):36. https:\/\/doi.org\/10.1186\/s40463-021-00519-9.","journal-title":"J Otolaryngol Head Neck Surg"},{"issue":"1","key":"1135_CR41","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40463-023-00657-2","volume":"52","author":"Y Chan","year":"2023","unstructured":"Chan Y, Thamboo AV, Han JK, Desrosiers M. Remission: does it already exist in chronic rhinosinusitis with nasal polyposis? J Otolaryngol Head Neck Surg. 2023;52(1):50. https:\/\/doi.org\/10.1186\/s40463-023-00657-2.","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"1135_CR42","doi-asserted-by":"publisher","unstructured":"De Corso E, Settimi S, Montuori C, Cantiani A, Corb\u00f2 M, Di Bella GA, et al. How to manage recurrences after surgery in CRSwNP patients in the biologic era: a narrative review. Acta Otorhinolaryngol Ital. 2023;43(Suppl. 1):S3-S13. https:\/\/doi.org\/10.14639\/0392-100X-suppl.1-43-2023-01 .","DOI":"10.14639\/0392-100X-suppl.1-43-2023-01"},{"key":"1135_CR43","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1398-9995.2011.02709.x","volume":"67","author":"D Jarvis","year":"2012","unstructured":"Jarvis D, Newson R, Lotvall J, Hastan D, Tomassen P, Keil T, et al. Asthma in adults and its association with chronic rhinosinusitis: The GA2LEN survey in Europe. Allergy. 2012;67:91\u20138. https:\/\/doi.org\/10.1111\/j.1398-9995.2011.02709.x.","journal-title":"Allergy"},{"issue":"7","key":"1135_CR44","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3390\/jpm12071096","volume":"12","author":"V Seccia","year":"2022","unstructured":"Seccia V, D\u2019Amato M, Scioscia G, Bagnasco D, Di Marco F, Fadda G, et al. Management of Patients with Severe Asthma and Chronic Rhinosinusitis with Nasal Polyps: A Multidisciplinary Shared Approach. J Pers Med. 2022;12(7):1096. https:\/\/doi.org\/10.3390\/jpm12071096.","journal-title":"J Pers Med"},{"issue":"3","key":"1135_CR45","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","volume":"9","author":"TM Laidlaw","year":"2021","unstructured":"Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP. Chronic Rhinosinusitis with Nasal Polyps and Asthma. J Allergy Clin Immunol Pract. 2021;9(3):1133\u201341. https:\/\/doi.org\/10.1016\/j.jaip.2020.09.063.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"26","key":"1135_CR46","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486\u201396. https:\/\/doi.org\/10.1056\/NEJMoa1804092.","journal-title":"N Engl J Med"},{"issue":"2","key":"1135_CR47","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.jaip.2021.12.014","volume":"10","author":"ID Pavord","year":"2022","unstructured":"Pavord ID, Hanania NA, Corren J. Controversies in allergy: choosing a biologic for patients with severe asthma. J Allergy Clin Immunol Pract. 2022;10(2):410\u20139. https:\/\/doi.org\/10.1016\/j.jaip.2021.12.014.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1135_CR48","doi-asserted-by":"publisher","unstructured":"Otten J, van der Lans R, de Corso E, Dziadziulia K, Hilvering B, Weersink E, et al. Evaluation of switching or simultaneous use of biologic treatment in patients with severe chronic rhinosinusitis with nasal polyps and severe asthma. Considerations in clinical decision making. Expert Rev Clin Immunol. 2023;19(8):1041\u20139. https:\/\/doi.org\/10.1080\/1744666X.2023.2218617.","DOI":"10.1080\/1744666X.2023.2218617"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-024-01135-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-024-01135-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-024-01135-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T11:02:39Z","timestamp":1713438159000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-024-01135-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1135"],"URL":"https:\/\/doi.org\/10.1007\/s11882-024-01135-z","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"value":"1529-7322","type":"print"},{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"31 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this paper was updated to correct the family name of Matteo Alicandri Ciufelli.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"EDC has received fees for consultation, speaker activity, and advisory boards from Sanofi, Regeneron, GlaxoSmithKline (GSK), Novartis and AstraZeneca. GO has received fees for consultation, speaker activity, and served on advisory boards for Sanofi, GSK, and Novartis. CP has received fees for consultation, speaker activity, advisory boards from Sanofi, Regeneron, GSK, Novartis, Chiesi, Firma. EC has received lecture fees from and participated in experts\u2019 board meetings of GSK, Novartis, Sanofi, NOOS, and AstraZeneca. MC has received speaker and consultancy fees from Astra Zeneca, GSK, and Sanofi. CC has received lecture fees and participated in experts\u2019 board meetings of GSK, Novartis, and Sanofi. G Senna has received speaker fees from Sanofi, AstraZeneca, and GSK. ST fees for lectures and advisory boards for GSK and SANOFI. VS has received lecture fees and participated in experts\u2019 board meetings of GSK, Novartis, Sanofi, and AstraZeneca. MG has received lecture fees and participated in experts\u2019 board meetings of GSK and Sanofi. MT has received consulting fees from Sanofi, GSK, and Novartis. FP has received consulting fees from Sanofi, Novartis, Chiesi, Menarini, Firma, and Deca. FRC has received lecture fees and participated in experts board meetings of GSK, Novartis, and Sanofi. ILM has received lecture fees and participated in experts\u2019 board meetings of Sanofi. The other authors declare no conflict of interest. LC has received fees for consultation, speaker activity, and advisory boards from Sanofi, GlaxoSmithKline (GSK), Novartis, Menarini, Thermofisher, ALK and AstraZeneca. EN has received speaker and consultancy fees from Abbvie, Leo-Pharma, Novartis, Astra Zeneca, GSK, and Sanofi. MAC has received fees for consultation, speaker activity, advisory boards from Sanofi. GB has received lecture fees and participated in experts\u2019 board meetings of Sanofi, GSK, Novartis, Abiogen, Aurora Biopharma. CC has received fees for consultation, speaker activity, and advisory boards from Sanofi, GlaxoSmithKline (GSK), menarini, Chiesi and AstraZeneca. MG has received advisory board fees or speaker fees from GlaxoSmithKline, Novartis, Sanofi-Genzyme, Valeas, DMG Italia, FIRMA, Aurora Biofarma, and Fenix Pharma. EH has received speaker activity and advisory board participation fees from Novartis, GlaxoSmithKline, Sanofi, Regeneron, AstraZeneca, Stallergenes-Greer, Circassia, and Nestl\u00e8 Purina. AM has received speaker\u2019s fees from Amicus Therapeutics, AstraZeneca, GSK, Novartis, Sanofi and Takeda and honoraria for attending advisory board meetings with, AstraZeneca, GSK, Novartis, Sanofi and Chiesi. AV has received speaker\u2019s fees from AstraZeneca, GSK, Novartis, Sanofi and Chiesi and honoraria for attending advisory board meetings with, AstraZeneca, GSK, Novartis, Sanofi. PFM has received lecture fees and participated in experts board meetings of GSK and Sanofi. EP, SG, DM, has none conflict of interest. GS has received speaker fee and research grant by AstraZeneca, GSK, Novartis, Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}